Scholar Rock is trading at $47.35, up 4.07%, with the move appearing linked to broader biotech-sector strength rather than a company-specific catalyst.

  • Moderna raised its 2026 revenue-growth outlook to 15%–25% after strong results, supporting broader biotech sentiment.
  • Scholar Rock’s next quarterly results are scheduled for November 10.
  • Volume or unusual trading activity was not established.